Insider Trading Alert - MACK, POOL And GPS Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, June 24, 2014, 63 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $452.23 to $11,250,120.00.

Highlighted Stocks Traded by Insiders:

Merrimack Pharmaceuticals (MACK) - FREE Research Report

Porter Michael E, who is Director at Merrimack Pharmaceuticals, bought 32,390 shares at $6.84 on June 24, 2014. Following this transaction, the Director owned 568,255 shares meaning that the stake was boosted by 6.04% with the 32,390-share transaction.

The shares most recently traded at $7.35, up $0.51, or 6.94% since the insider transaction. Historical insider transactions for Merrimack Pharmaceuticals go as follows:

  • 4-Week # shares bought: 4,000
  • 12-Week # shares bought: 90,000
  • 24-Week # shares bought: 90,000

The average volume for Merrimack Pharmaceuticals has been 2.2 million shares per day over the past 30 days. Merrimack Pharmaceuticals has a market cap of $723.8 million and is part of the health care sector and drugs industry. Shares are up 34.31% year-to-date as of the close of trading on Tuesday.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer primarily in the United States. Currently, there are 3 analysts who rate Merrimack Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on MACK - FREE

TheStreet Quant Ratings rates Merrimack Pharmaceuticals as a sell. Among the areas we feel are negative, one of the most important has been weak operating cash flow. Get the full Merrimack Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Verastem Shares Are Exploding 50% -- Here's Why

Otonomy Shares Rebound After Wednesday's Drop- Biotech Movers

Biotech Movers: Array Shares Rise on Bristol-Myers Collaboration

Trevena, Synergy Lead Biotech Movers

These 5 Stocks Under $10 Could Explode Up Soon